New Tool Developed to Predict Colorectal Cancer Risk
News Jan 01, 2009
A new online tool for calculating colorectal cancer risk in men and women age 50 or older has been launched, based on a new risk-assessment model developed by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health.
The new tool may assist health care providers and their patients in making informed choices about when and how to screen for colorectal cancer and can be used in designing colorectal cancer screening and prevention trials.
An article describing the new risk-assessment model and a second article describing its validation appear online December 29, 2008, in the Journal of Clinical Oncology. The risk assessment tool is available on the NCI Web site at www.cancer.gov/colorectalcancerrisk, and people using this tool should work with their health care providers to interpret the results.
Using easily obtainable information the tool provides an estimate of an individual's risk of developing colorectal cancer over certain time periods. This risk-assessment model is said to be the first to provide an absolute risk estimate for colorectal cancer for the general, non-Hispanic white population age 50 or older in the United States.
"Much like the NCI's breast cancer and melanoma risk assessment tools, this new colorectal cancer risk assessment tool should prove useful not only in counseling patients on their individual risk, but also in helping plan the type and frequency of screening interventions," said NCI Director John E. Niederhuber, M.D. "As we move toward an era of personalized medicine, the ability to assess an individual patient's cancer risk and thereby improve our ability to apply appropriate prevention measures is of vital importance."
"This colorectal cancer risk model should provide physicians and their patients a new tool to help make informed decisions about cancer screening and other cancer prevention strategies. It may also assist policy makers in evaluating the usefulness of current and future population colorectal cancer screening approaches," said Andrew Freedman, Ph.D., lead author of the paper that describes the development of the risk-assessment model.
To test the accuracy of the risk-assessment model, the researchers compared expected numbers of colorectal cancer cases predicted by the model to the observed numbers of cases identified in the NIH-AARP Diet and Health Study, a large study that follows AARP members and collects information about nutrition and health.
From information about individual risk factors that was collected when participants entered the study, the researchers used the new model to estimate the number of men and women who would be expected to develop colorectal cancer.
According to Ruth Pfeiffer, Ph.D., who was the senior author of the validation study, "The colorectal cancer risk-assessment tool predicted the numbers of colorectal cancer diagnoses well overall, and in most risk categories."
Because the majority of participants in the two case-control studies used to develop the model were non-Hispanic whites age 50 or older, the researchers were unable to estimate relative risks for other age and racial/ethnic groups.
In addition to the standard Web tool, a mobile Web-based version for use on Internet-enabled mobile devices and the source code for the model will soon be made available to researchers. It is important that users of the online tool work with their primary health care provider to interpret the results and plan a course of action regarding colorectal cancer screening.
Engineering the Gut Microbiome with 'Good' Bacteria May Help Treat Crohn's DiseaseNews
Researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn's disease. Replacement of the offending bacteria with "good" bacteria may offer an effective treatment approach.READ MORE
Obese and Anorexic Women Have Low Levels of ‘Feel Good’ NeurosteroidNews
Researchers have found that women at opposite extremes of the weight spectrum have low levels of the neuroactive steroid allopregnanolone, a metabolite of the hormone progesterone. Gas chromatography and mass spectrometry were used to pick up extremely small levels of these chemicals in blood serum, saliva and brain tissue.READ MORE